Volume 1, Issue 3 (2015)                   Pharm Biomed Res 2015, 1(3): 1-10 | Back to browse issues page

DOI: 10.18869/acadpub.pbr.1.3.1


XML Print


1- Department of Pharmacology and Pharmacy Practice, Annamacharya College of Pharmacy, Rajampet, India
Abstract:   (2745 Views)

Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. Dabigatran etexilate is an orally effective anti-thrombin drug, several animal and human trials were conformed the efficacy of this drug in reduction of major bleeding in related to acute coronary syndrome, knee replacement surgery and venous thromboembolism conditions. The therapeutic use of this drug also shows limited side effects to select the dabigatran as promising therapeutic agent in bleeding complications.

Full-Text [PDF 481 kb]   (1508 Downloads)    
Type of Study: Review article | Subject: Pharmacology